Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term Effects of Empagliflozin on Divalent Ions in ADPKD
NCT06435858Phase 2Completed
- Sponsor
- Kantonsspital Graubünden
- Start
- Sep 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Kantonsspital Graubünden. Started Sep 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06435858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435858.